Kevan Herold MD

Professor of Immunobiology and of Medicine (Endocrinology); Deputy Director for Translational Science, YCCI

Clinical Interests

Diabetes mellitus; hypoglycemia; endocrinology


Board Certifications

1985
Endocrinology & Metabolism, Board Certified
1982
Internal Medicine, Board Certified

Patient Care Locations

 
kevan_heroldfaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Autoantibody Positive, High Risk, Impaired Glucose Tolerance, and Non-diabetic Relatives at Risk for Type 1 Diabetes Anti-CD3 (Teplizumab) for Prevention of Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus A Phase 1 Safety trial of CD4+CD1271o/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes
Abnormal Glucose Tolerance and Type 1 Diabetes CTLA-4 Ig (Abatacept) FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS

Edit Profile